Ozone autohemotherapy treats a portion of a person's own blood with a reactive form of oxygen to trigger a controlled stress that strengthens the body's defenses. The best-supported signal is reduced inflammation; fair evidence exists for stubborn wounds and some chronic pain. Claims of slowed aging rest on theory alone. The most serious harms track unsafe technique or excessive dose. (Full Review)
| Marker | Target | Why |
|---|---|---|
| G6PD enzyme activity | Normal (non-deficient) | Identifies people at high risk of oxidative red-cell rupture |
| Hemoglobin / Hematocrit | Hgb ~13.5–15 g/dL (men), ~12.5–14 g/dL (women) | Detects anemia and ongoing red-cell loss from hemolysis |
| Haptoglobin | Within normal, not low | A falling level flags red-cell breakdown (hemolysis) |
| hs-CRP | < 1.0 mg/L | Tracks the systemic inflammation the therapy aims to lower |
| IL-6 | Low-normal for the assay | A more specific inflammatory signal to gauge response |
| Fasting glucose / HbA1c | Glucose 80–90 mg/dL; HbA1c < 5.4% | Relevant when treating diabetic wounds or metabolic inflammation |
| eGFR | > 60 mL/min/1.73m² | Baseline organ-function context in older or comorbid adults |
Cadence: Baseline, after several sessions, and at course completion; maintenance rechecked every 6–12 months